# Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone

> **NCT01605084** · PHASE3 · WITHDRAWN · sponsor: **Bristol-Myers Squibb**

## Conditions studied

- HIV

## Interventions

- **DRUG:** Atazanavir
- **DRUG:** Darunavir
- **DRUG:** Ritonavir
- **DRUG:** Optimized NRTI backbone

## Key facts

- **NCT ID:** NCT01605084
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-06-30
- **Primary completion:** 2014-08-31
- **Final completion:** 2014-08-31
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2023-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01605084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01605084, "Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01605084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*